Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Previous Hold Today ADMS ranks #2048 as HOLD CANDIDATE #2048 Next Hold

ADMS stock forecast Adamas Pharmaceuticals

ADMS stock forecast

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Cardiovascular Systems Inc (NASDAQ: CSII ) Cortexyme Inc (NASDAQ: CRTX ) EXACT Sciences Corporation (NASDAQ: EXAS ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Merck & Co., Inc. (NYSE: MRK ) ( Keytruda received one more approval, this time for metastatic small cell lung cancer in patients who have been treated previously) Novocure Ltd (NASDAQ: NVCR ) Repligen Corporation (NASDAQ: RGEN ) SAGE Therapeutics Inc (NASDAQ: SAGE ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Zynex Inc. (NASDAQ: ZYXI ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 18) Abeona Therapeutics Inc (NASDAQ: ABEO ) BioNano Genomics Inc (NASDAQ: BNGO ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kezar Life Sciences Inc (NASDAQ: KZ ) Mediwound Ltd (NASDAQ: MDWD ) MEREO BIOPHARMA/ADR (NASDAQ: MREO ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Adamas Parkinson's Drug Reduces Frequency And Duration of Daily Episodes of Dyskinesia and OFF Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) announced retrospective data analysis from pooled Phase 3 study of its Gocovri extended release capsules, which showed that the drug reduced both the number and duration of troublesome dyskinesia and OFF episodes relative to placebo such that patients experienced approximately half as many …

Read more

What Makes Adamas (ADMS) a New Buy Stock
01:00pm, Tuesday, 18'th Jun 2019
Adamas (ADMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.

Read more

New commercial chief at Adamas Pharma
08:48pm, Thursday, 30'th May 2019

Read more

Adamas (ADMS) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 14'th May 2019
Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read more

Adamas (ADMS) delivered earnings and revenue surprises of 4.42% and -8.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 8) Alcon AG (NYSE: ALC ) BioSig Technologies Inc (NASDAQ: BSGM ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 8) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aquestive Therapeutics Inc (NASDAQ: AQST )(reacted to first-quarter results) Arbutus Biopharma Corp (NASDAQ: ABUS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Flexion Therapeutics Inc (NASDAQ: FLXN ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Opko Health Inc. (NASDAQ: OPK )(reacted to Q1 results) Osmotica Pharmaceuticals PLC (NASDAQ: OSMT ) Retrophin Inc (NASDAQ: RTRX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Sensus Healthcare Inc (NASDAQ: SRTS ) Stock In Focus Novartis to Buy Dry Eye Disease Drug From Takeda For $3.4B Novartis AG (NYSE: NVS ) announced an agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK ) to acquire the assets associated with Xildra, chemically lifitefgrast ophthalmic solution, 5 percent worldwide for a $3.4 billion payment upfront and potential milestone payments up to $1.9 billion.

Read more

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 9) Edap Tms SA (NASDAQ: EDAP ) INmune Bio Inc (NASDAQ: INMB ) NGM Biopharmaceuticals Inc (NASDAQ: NGM )(began trading on the Nasdaq last week) PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS )(announced obtaining Breakthrough Therapy Designation for its reversal agent for blood thinner) Down In The Dumps (Biotech stocks hitting 52-week lows on April 9) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Evoke Pharma Inc (NASDAQ: EVOK ) Revance Therapeutics Inc … Full story available on Benzinga.com

Read more

Here we will take a look at several key ratios for Daiichikosho Co., Ltd. (TSE:7458), starting with the Book to Market (BTM) ratio. Value investors seek stocks with high BTMs for their portfolios. The

Read more

Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Adamas Pharmaceu

Read more

Many individuals strive to expand their wealth by investing in the stock market. There are countless factors that come in to play when analyzing which stocks to invest in. Along with all the tangible

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank